Allocetra for Knee Arthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a multicenter, randomized, double-blind, placebo-controlled, Phase IIb study to evaluate intra-articular (IA) injections of Allocetra in participants with moderate-to-severe age related symptomatic primary knee osteoarthritis (OA).
Who Is on the Research Team?
Lital Weinfeld Bergman
Principal Investigator
Senior Director of Clinical Operations
Are You a Good Fit for This Trial?
This trial is for people aged 64 or older with moderate-to-severe knee osteoarthritis confirmed by X-ray, who have not improved after trying at least two other treatments. Participants must be able to stop certain medications and meet specific reproductive health requirements.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive three ultrasound-guided intra-articular injections of Allocetra or placebo on Days 0, 14, and 28
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Allocetra
Trial Overview
The study compares injections of Allocetra directly into the knee joint versus placebo (inactive injection) in patients with knee osteoarthritis. It is randomized, double-blind, and placebo-controlled, meaning neither doctors nor participants know which treatment they receive.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Three intra-articular injections of Allocetra at a selected dose, into the index knee.
Three intra-articular injections of placebo into the index knee.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Enlivex Therapeutics Ltd.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.